Low-dose radiation and immunotherapy before surgery for head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed, advanced head and neck cancer (oral cavity, throat, voice box, or lower throat) that has not been treated yet.
- Your cancer tests positive for a protein called PD-L1 (CPS score of 1 or higher).
- You are between 18 and 75 years old.
- You are healthy enough for daily activities (ECOG score 0 or 1) and expected to live more than 6 months.
- Your organ function (blood counts, liver, kidneys, thyroid) is adequate based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a less extensive surgery to the standard surgery for patients with advanced head and neck cancer who have responded well to initial chemotherapy and immunotherapy. The goal is to see if a smaller operation can be just as effective while causing fewer side effects.
This trial compares giving immunotherapy alone versus immunotherapy plus focused radiation before surgery for head and neck cancer. The goal is to see if adding radiation helps shrink the tumor and improve outcomes.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and N-803) with or without special immune cells (PD-L1 t-haNK cells) before surgery for head and neck cancer. The goal is to see if this treatment can shrink the cancer or improve the outcome after surgery.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a combination of immunotherapy (AK112) and chemotherapy (AP regimen) given before surgery to treat locally advanced head and neck squamous cell carcinoma. The goal is to see if this approach can shrink tumors and improve outcomes for patients who are eligible for surgery.
This trial tests a combination of drugs before surgery for head and neck cancer. It aims to shrink tumors and improve outcomes, and the study compares adding another targeted drug to the standard combination.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.